Ovarian Epithelial Carcinoma clinical trials at UC Davis
3 in progress, 1 open to eligible people
BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
“Volunteer for research and contribute to discoveries that may improve health care for you, your family, and your community!”
open to eligible people ages 18 years and up
The investigational drug to be studied in this protocol, BCA101, is a first-in-class compound that targets both EGFR with TGFβ. Based on preclinical data, this bifunctional antibody may exert synergistic activity in patients with EGFR-driven tumors.
Sacramento, California and other locations
Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery
Sorry, in progress, not accepting new patients
Study to compare the safety and efficacy of oregovomab versus placebo, administered in combination with specific cycles of a standard six-cycle chemotherapy regimen (paclitaxel and carboplatin), for the treatment of subjects with newly diagnosed advanced ovarian cancer who have undergone optimal debulking.
Sacramento, California and other locations
Standardized Extract of Cultured Lentinula Edodes Mycelia (AHCC®) in Ovarian Cancer Patients on Adjuvant Chemotherapy
“Join our study of AHCC (a shiitake mushroom extract) for quality of life in ovarian cancer patients!”
Sorry, in progress, not accepting new patients
This is a pilot phase, randomized, double-blinded feasibility pilot study of AHCC in participants with ovarian cancer.
Sacramento, California
Our lead scientists for Ovarian Epithelial Carcinoma research studies include Andrew Birkeland, MD Hui Chen, MD.
Last updated: